MEMBER INTRODUCITONS

MANAGEMENT TEAM

Shin Hatou

Founder & CEO

Shin Hatou,
M.D., Ph.D.

1998
Keio University, M.D.
2002
Research Assistant, Keio University (Ophthalmology)
2008
Assistant Professor, Keio University (Ophthalmology)
2013
Specially Appointed Lecturer, Keio University (Ophthalmology)
2015
Founder & CEO, Cellusion
Joji Hayashida

EVP & COO / Head of Business Strategy

Joji Hayashida,
MBA, Ph.D.

2009
Postdoctoral Fellow, Memorial Sloan Kettering Cancer Center
2011
Senior Researcher, Astellas Pharma
2019
CFO, Executive Officer, Cellusion
2020
CFO, Board Director, Cellusion
2021
CFO & COO, Board Director, Cellusion
2022
EVP & COO, Cellusion
Takuya Kaneko

CFO / Head of Financial Strategy

Takuya Kaneko,
LL.M.

1998
The Export-Import Bank of Japan
(currently Japan Bank for International Cooperation)
2006
Morgan Stanley Japan Securities
(currently Mitsubishi UFJ Morgan Stanley Securities)
2017
Executive Director, Mitsubishi UFJ Morgan Stanley Securities
2022
CFO, Cellusion
2023
CFO, Executive Officer, Cellusion
2024
CFO, Board Director, Cellusion
武村忍

Director, IP & Legal Dept.

SHINOBU TAKEMURA, Patent Attorney

2000
Hitachi Software Engineering (currently Hitachi Solutions)
2006
Oncolys BioPharma
2008
SBI Intechstra
2011
Oji Paper (currently Oji Holdings)
2019
YAMASHIN-FILTER
2022
Director, IP & Legal Department, Cellusion
2024
Executive Officer, Director, IP & Legal Department, Cellusion
Nobuyuki Imai

CDO / Head of R&D

Nobuyuki Imai

1992
Researcher, Kyowa Hakko Kogyo
(currently Kyowa Kirin)
2000
Manager, Kyowa Pharmaceutical
2017
Director, Kyowa Kirin
2021
CDO, Cellusion

OUTSIDE DIRECTORS

Joyce Cheng

Outside Director

Joyce Cheng

2013
Rakuten Group
2016
Assistant Manager & China Country Manager, Rakuten Group
2017
Investment Director, Industrial Technology Investment Corporation
(-present)
2022
Outside Director, Cellusion
Toru J. Seo

Outside Director

Toru J. Seo,
MBA, Ph.D.

2000
Assistant Professor, Columbia University
2006
Manager, GlaxoSmithKline
2006
Banyu Pharmaceutical
2009
Director, Merck & Co.
2012
Deputy General Manager, Taisho Pharmaceutical
2015
Senior Director, Japan ES&I lead, Pfizer Inc
2019
APAC Lead and Senior Director, Pfizer Inc
2021
CEO, BioLite Japan (-present)
2021
CEO, Lucidaim (-present)
2021
Outside Director, Cellusion
2022
CEO, Newsight Tech Angels (-present)
Tomokatsu Hongo

Outside Director

Tomokatsu Hongo,
Ph.D.

2006
Summit Pharmaceuticals International Corporation (SPI)
2010
Head of Biology Group, SPI
2016
Executive Officer, Keio Innovation Initiative (-present)
2017
Outside Director, Cellusion
Hiroaki Kobayashi

Outside Director

Hiroaki Kobayashi,
M.D., MBA

2010
Physician, The University of Tokyo Hospital and Hitachi General Hospital
2014
Medical Director, Japanese Organization for Medical Device Development
2018
Manager, Boston Scientific Corporation Japan
2019
Principal, The University of Tokyo Edge Capital Partners
(-present)
2021
Outside Corporate Auditor, Cellusion
2023
Outside Director, Cellusion
Yoshiharu Asai

Outside Director

Yoshiharu Asai

2010
Daiwa Securities Capital Markets Co. Ltd. (currently Daiwa Securities Co. Ltd.)
2018
Innovation Network Corporation of Japan (currently INCJ, Ltd.)
2020
Principal, JIC Venture Growth Investments Co., Ltd. (-present)
2023
Outside Director, Cellusion

CORPORATE AUDITORS

Ikuo Mashimo

Outside Corporate Auditor (Full-Time)

Ikuo Mashimo

1979
Special Reference Laboratories
(currently SRL)
2005
Executive Officer, General Manager, SRL
2007
Director, General Manager, SRL
2012
Corporate Auditor, Fujirebio
2017
Executive Director, General Manager, SRL
2018
Corporate Auditor, IDAC Theranostics
2022
Corporate Auditor, Cellusion
Tomotaka Goji

Outside Corporate Auditor

Tomotaka Goji, MBA, Ph.D.

1996
Ministry of International Trade and Industry (currently The Ministry of Economy, Trade and Industry)
2004
The University of Tokyo Edge Capital Co., Ltd.
2015
Managing Director, Japan Venture Capital Association
2018
CEO and President, Managing Partner, The University of Tokyo Edge Capital Partners Co., Ltd. (-present)
2022
Vice Chairman, Japan Venture Capital Association
2023
Chairman, Japan Venture Capital Association (-present)
2023
Outside Corporate Auditor, Cellusion
Norihisa Kobayashi

Outside Corporate Auditor

Norihisa Kobayashi

1988
The Hokkaido Takushoku Bank, Ltd.
1998
Daiwa Securities Co. Ltd.
2018
Outside Full-Time Auditor, Japan Management Succession Support Co. Ltd.
2023
Outside Corporate Auditor, Cellusion
2024
Outside Full-Time Auditor, ELESTYLE, Inc. (-present)
Hiromi Furushima

Outside Corporate Auditor

Hiromi Furushima

1994
The Legislative Bureau of the House of Representatives
1997
KOGA & PARTNERS
2000
Nishimura & Partners (currently Nishimura & Asahi)
2006
Ito & Mitomi (currently Morrison Foerster)
2011
Novartis Holding Japan K.K
2012
Head, Legal & Compliance Office, SANDOZ K.K.
2014
Head of Pharma Legal Department, Novartis Pharma K.K.
2016
Corporate Officer, General Counsel, Head of Legal & IP and Country Legal Head, Novartis Pharma K.K.
2022
Director, International Legal, Alnylam Japan K.K. (-present)
2022
Outside Director, PRISM BioLab Co.,Ltd. (-present)
2023
Outside Corporate Auditor, Cellusion

ADVISORS

Sophie X. Deng

Scientific Advisor

Sophie X. Deng,
M.D., Ph.D.

Professor, University of California, Los Angeles
Director, UCLA Stein Eye Institute
An authority on corneal transplantation; has won numerous awards

  • University of California, Los Angeles
  • UCLA Stein Eye Institute
  • The Illinois Eye and Ear Infirmary
  • The University of Rochester
Ula V. Jurkunas

Scientific Advisor

Ula V. Jurkunas,
M.D.

Associate Professor, Harvard Medical School
Associate Director, Massachusetts Eye and Ear
Member, Cornea Center of Excellence
An expert in corneal diseases; has won numerous awards

  • Harvard Medical School
  • Massachusetts Eye and Ear
  • Boston University
  • University of Louisville
Jun Shimazaki

Scientific Advisor

Jun Shimazaki,
M.D., Ph.D

Professor Emeritus of Tokyo Dental College
A specialist on corneal transplantation, corneal regenerative medicine, and treatment for severe ocular surface disease.

  • Tokyo Dental College
  • Shimazaki Eye Clinic
  • Keio University Hospital
  • Saiseikai Kanagawa Hospital
Yoshinori Shinoki

R&D Advisor

Yoshinori Shinoki

Has been involved in numerous clinical development projects for leading global pharmaceutical companies and CROs. Currently serves as CEO of his own consulting firm, Pharma Initiative Support

  • Parexel
  • Eli Lilly
Shunta Ide

Management Advisor

Shunta Ide

Has over 30 years experience in the financial industry, including as Executive Officer, SMBC Nikko Securities, Managing Director, Morgan Stanley MUFG Securities, and at The Bank of Tokyo-Mitsubishi. Currently serves as CEO of his own consulting firm, KOMABA Planning

  • SMBC Nikko Securities
  • Morgan Stanley MUFG Securities
  • Morgan Stanley
  • The Bank of Tokyo-Mitsubishi
Wataru Amano

PR Advisor

Wataru Amano,
MBA

Has extensive experience in corporate branding and promotion having worked at PR companies, including Signal and Parco Digital Marketing. Former COO of Vector group company, Signal

  • PARCO
  • VECTOR
  • PERSOL CAREER
  • Light